CytomX Depreciation And Amortization vs Selling General Administrative Analysis
CTMX Stock | USD 1.89 0.11 5.50% |
CytomX Therapeutics financial indicator trend analysis is way more than just evaluating CytomX Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytomX Therapeutics is a good investment. Please check the relationship between CytomX Therapeutics Depreciation And Amortization and its Selling General Administrative accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.
Depreciation And Amortization vs Selling General Administrative
Depreciation And Amortization vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytomX Therapeutics Depreciation And Amortization account and Selling General Administrative. At this time, the significance of the direction appears to have almost identical trend.
The correlation between CytomX Therapeutics' Depreciation And Amortization and Selling General Administrative is 0.98. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of CytomX Therapeutics, assuming nothing else is changed. The correlation between historical values of CytomX Therapeutics' Depreciation And Amortization and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of CytomX Therapeutics are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Depreciation And Amortization i.e., CytomX Therapeutics' Depreciation And Amortization and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | 0.98 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Selling General Administrative
Most indicators from CytomX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.Tax Provision is likely to rise to about 3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.8 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 69.6M | 53.2M | 99.0M | 53.9M | Total Revenue | 69.6M | 53.2M | 101.2M | 54.2M |
CytomX Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
CytomX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytomX Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 341.3M | 358.7M | 339.4M | 260.9M | 205.2M | 284.4M | |
Other Current Liab | 27.2M | 19.9M | 30.6M | 24.5M | 17.6M | 17.9M | |
Total Current Liabilities | 85.6M | 100.9M | 106.3M | 152.6M | 155.9M | 82.7M | |
Total Stockholder Equity | 51.1M | 49.8M | 89.4M | (85.8M) | (47.4M) | (45.1M) | |
Other Liab | 179.7M | 186.3M | 125.7M | 180.1M | 207.1M | 151.2M | |
Property Plant And Equipment Net | 32.8M | 29.4M | 25.3M | 21.0M | 16.2M | 14.9M | |
Current Deferred Revenue | 51.4M | 74.9M | 69.3M | 121.3M | 132.3M | 138.9M | |
Net Debt | (163.6M) | (167.0M) | (187.5M) | (175.6M) | (3.2M) | (3.4M) | |
Retained Earnings | (417.2M) | (450.1M) | (533.7M) | (722.9M) | (723.4M) | (687.3M) | |
Accounts Payable | 4.2M | 3.0M | 2.8M | 2.8M | 1.5M | 2.7M | |
Cash | 188.4M | 191.9M | 205.5M | 193.7M | 17.2M | 16.3M | |
Non Current Assets Total | 37.9M | 34.7M | 29.1M | 23.8M | 22.2M | 19.8M | |
Non Currrent Assets Other | 2.9M | (3.4M) | (3.7M) | (3.6M) | 83K | 78.9K | |
Other Assets | 2.9M | 25.6M | 1.8M | 944K | 1.1M | 1.0M | |
Cash And Short Term Investments | 296.1M | 316.1M | 305.2M | 193.7M | 174.5M | 253.8M | |
Net Receivables | 13K | 798K | 790K | 36.0M | 3.4M | 5.6M | |
Common Stock Shares Outstanding | 45.3M | 46.1M | 64.1M | 65.7M | 73.8M | 48.9M | |
Short Term Investments | 188.6M | 107.7M | 124.3M | 99.7M | 157.3M | 117.8M | |
Liabilities And Stockholders Equity | 341.3M | 358.7M | 339.4M | 260.9M | 205.2M | 284.4M | |
Non Current Liabilities Total | 204.6M | 207.9M | 143.7M | 194.0M | 96.7M | 167.7M | |
Other Current Assets | 7.2M | 7.1M | 4.3M | 7.5M | 5.0M | 5.2M | |
Other Stockholder Equity | 468.3M | 500.0M | 623.3M | 637.1M | 675.9M | 709.7M | |
Total Liab | 290.2M | 308.9M | 250.0M | 346.6M | 252.6M | 250.4M | |
Property Plant And Equipment Gross | 32.8M | 29.4M | 25.3M | 21.0M | 30.9M | 16.4M | |
Total Current Assets | 303.3M | 324.0M | 310.3M | 237.1M | 182.9M | 264.6M | |
Accumulated Other Comprehensive Income | 57K | (47K) | (242K) | 10K | 95K | 99.8K | |
Short Term Debt | 2.8M | 3.2M | 3.6M | 4.1M | 4.6M | 4.7M | |
Intangible Assets | 1.3M | 1.2M | 1.0M | 875K | 729K | 1.1M | |
Property Plant Equipment | 6.9M | 32.8M | 7.0M | 6.0M | 6.9M | 8.3M | |
Net Tangible Assets | 48.9M | 47.7M | 87.4M | (2.4M) | (2.8M) | (2.7M) | |
Retained Earnings Total Equity | (417.2M) | (450.1M) | (533.7M) | (623.6M) | (561.2M) | (533.1M) | |
Capital Surpluse | 446.0M | 468.3M | 500.0M | 623.3M | 716.8M | 474.2M | |
Non Current Liabilities Other | 850K | 207.9M | 143.7M | 262M | 3.9M | 3.7M | |
Net Invested Capital | 51.1M | 49.8M | 89.4M | (85.8M) | (47.4M) | (45.1M) | |
Net Working Capital | 217.7M | 223.1M | 204.0M | 84.5M | 27.0M | 25.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.21 | Revenue Per Share 1.533 | Quarterly Revenue Growth 0.764 | Return On Assets 0.0323 | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.